Pyrrolizidin-3-carbonsaeure | 2581-04-6

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: Pyrrolizidin-3-carbonsaeure
• 英文别名: Hexahydro-1H-pyrrolizine-3-carboxylic acid；2,3,5,6,7,8-hexahydro-1H-pyrrolizine-3-carboxylic acid
• CAS: 2581-04-6
• 化学式: C₈H₁₃NO₂
• 分子量: 155.197
• InChiKey: CLFIHFDKFSERQF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -1.3
• 重原子数：
  11
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.88
• 拓扑面积：
  40.5
• 氢给体数：
  1
• 氢受体数：
  3

文献信息

• PEPTIDES AND PEPTIDOMIMETIC COMPOUNDS, THE MANUFACTURING THEREOF AS WELL AS THEIR USE FOR PREPARING A THERAPEUTICALLY AND/OR PREVENTIVELY ACTIVE PHARMACEUTICAL COMPOSITION
  申请人：PETZELBAUER Peter

  公开号：US20100081787A1

  公开（公告）日：2010-04-01

  Peptides, peptidomimetics and derivatives thereof of the general formula I: H 2 N-GHRPX 1 - β -X 4 X 5 X 6 X 7 X 8 X 9 X 10 -X 11 (I), in which X 1 -X 10 denote one of the 20 genetically coded amino acids, wherein X 8 , X 9 and X 10 may also denote a single chemical bond; X 11 denotes OR 1 in which R 1 equals hydrogen or (C 1 -C 10 ) alkyl NR 2 R 3 with R 2 and R 3 are equal or different and denote hydrogen, (C 1 -C 10 ) alkyl, or a residue —W-PEG 5-60K , in which the PEG residue is attached via a suitable spacer W to the N-atom, or a residue NH—Y-Z-PEG 5-60K , in which Y denotes a chemical bond or a genetically coded amino acids from the group S, C, K or R and Z denotes a spacer, via which a polyethylene glycol (PEG)-residue can be attached, and their physiologically acceptable salts, and β denotes an amino acid, or a peptidomimetic element, which induces a bend or turn in the peptide backbone.

  通用公式I：H2N-GHRPX1-β-X4X5X6X7X8X9X10-X11(I)中的肽、肽类似物和衍生物，其中X1-X10表示20种遗传编码的氨基酸之一，其中X8、X9和X10也可以表示单一化学键；X11表示OR1，其中R1等于氢或(C1-C10)烷基NR2R3，其中R2和R3相同或不同，表示氢、(C1-C10)烷基，或者残基—W-PEG5-60K，其中PEG残基通过适当的间隔物W连接到N-原子，或者残基NH—Y-Z-PEG5-60K，其中Y表示化学键或来自S、C、K或R组的遗传编码氨基酸，Z表示间隔物，通过该间隔物可以连接聚乙二醇（PEG）残基，并且它们的生理上可接受的盐，β表示氨基酸或诱导肽骨架中弯曲或转弯的肽类或肽类似元素。
• BBETA-15-42 FOR THE TREATMENT OF VIRAL ENDOTHELITIS
  申请人：Johann Wolfgang Goethe-Universität Frankfurt am Main

  公开号：EP3912679A1

  公开（公告）日：2021-11-24

  The invention is based on the fibrin-derived peptides as therapeutic compounds for the treatment of inflammatory complications of virally caused diseases, such as a diffuse inflammation of the endothelium, also known as systemic endotheliitis or vasculitis and related disorders. The use of certain fibrin derived peptides and analogues of these compounds resulted in a surprisingly effective patient recovery.

  本发明基于纤维蛋白衍生肽作为治疗化合物，用于治疗病毒引起的疾病的炎症并发症，如内皮细胞弥漫性炎症，也称为系统性内皮细胞炎或血管炎及相关疾病。使用某些纤维蛋白衍生肽和这些化合物的类似物后，病人的康复效果令人惊讶。
• C5a Receptor antagonists
  申请人：Hummel Gerd

  公开号：US20060183883A1

  公开（公告）日：2006-08-17

  The invention relates to a C5a receptor antagonist of structure (I), wherein X1 is a radical having a mass of about 1-300 and stands for R5-, R5-CO—, R5-N(R6)-CO—, R5-O—CO—, R5-SO 2 —, R5-N(R6)-SO 2 —, R5-N(R6)-, R5-N(R6)-CS—, R5-N(R6)-C(NH)—, R5-CS—, R5-P(O)OH—, R5-B(OH)—or R5-CH═N—O—CH 2 —CO—, wherein R5/R6 represent H, F, hydroxy, alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, heterocyclyl, substituted heterocyclyl, arylalkyl, substituted arylalkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, acyl, substituted acyl, alkoxy, alkoxyalkyl, substituted alkoxyalkyl, aryloxyalkyl or substituted aryloxyalkyl; X2=radical (biological bonding properties of a mimicrying phenylalanine unit); X3/X4=spacer (amino acids, amino-acid analogs and amino-acid derivatives); X5=radical (biological bonding properties of a mimicrying cyclohexylalanine or homoleucine unit); X6=radical (biological bonding properties of a mimicrying tryptophan unit); X7=radical (biological bonding properties of a mimicrying norleucine or phenylalanine unit), a chemical bond being formed between X3 and X7.

  本发明涉及结构（I）的 C5a 受体拮抗剂，其中 X1 是质量约为 1-300 的基团，代表 R5-、R5-CO-、R5-N(R6)-CO-、R5-O-CO-、R5-SO 2 -、R5-N(R6)-SO 2 -、R5-N(R6)-、R5-N(R6)-CS-、R5-N(R6)-C(NH)-、R5-CS-、R5-P(O)OH-、R5-B(OH)-或 R5-CH═N-O-CH 2 -CO-，其中 R5/R6 代表 H、F、羟基、烷基、取代的烷基、环烷基、取代的环烷基、杂环烷基、取代的杂环烷基、芳烷基、取代的芳烷基、芳基、取代的芳基、杂芳基、取代的杂芳基、酰基、取代的酰基、烷氧基、烷氧基烷基、取代的烷氧基烷基、芳氧基烷基或取代的芳氧基烷基；X2=自由基（模拟苯丙氨酸单元的生物键特性）；X3/X4=间隔物（氨基酸、氨基酸类似物和氨基酸衍生物）； X5=放射性（拟态环己基丙氨酸或高亮氨酸单元的生物键合特性）； X6=放射性（拟态色氨酸单元的生物键合特性）； X7=放射性（拟态去甲亮氨酸或苯丙氨酸单元的生物键合特性），X3 和 X7 之间形成化学键。
• C5A RECEPTOR ANTAGONISTS
  申请人：Jerini AG

  公开号：EP1838725A1

  公开（公告）日：2007-10-03
• PEPTIDES, PEPTIDOMIMETICS AND DERIVATIVES THEREOF, THE MANUFACTURING THEREOF AS WELL AS THEIR USE FOR PREPARING A THERAPEUTICALLY AND/OR PREVENTIVELY ACTIVE PHARMACEUTICAL COMPOSITION
  申请人：Fibrex Medical Research & Development GmbH

  公开号：EP2274328A1

  公开（公告）日：2011-01-19